The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description

John McGonigle(Imperial College London), J.F.W. Deakin(University of Manchester), Rebecca Elliott(University of Manchester), Louise M. Paterson(Imperial College London), Karen D. Ersche(University of Cambridge), John Suckling(University of Cambridge), Csaba Orbán(Imperial College London), Remy Flechais(Imperial College London), Anna Murphy(University of Manchester), Adam Waldman(Royal Society of Edinburgh), Liam J. Nestor(GlaxoSmithKline (United Kingdom)), Rexford D. Newbould(LivaNova (United Kingdom)), Anne Lingford‐Hughes(Hammersmith Hospital), Trevor W. Robbins(University of Cambridge), Jonathan Nash(Imperial College London), Laurence Reed(Imperial College London), Dana Smith(University of Cambridge), Eleanor Taylor(University of Manchester), David Nutt(Imperial College London)
Journal of Psychopharmacology
October 4, 2016
Cited by 21


Related Papers